Ontology highlight
ABSTRACT: Background
Mantle cell lymphoma (MCL) is a distinct clinical pathologic subtype of B cell non-Hodgkin's lymphoma often associated with poor prognosis. New therapeutic approaches based on boosting anti-tumor immunity are needed. MCL is associated with overexpression of cyclin D1 thus rendering this molecule an interesting target for immunotherapy.Methods
We show here a novel strategy for the development of recombinant vaccines carrying cyclin D1 cancer antigens that can be targeted to dendritic cells (DCs) via CD40.Results
Healthy individuals and MCL patients have a broad repertoire of cyclin D1-specific CD4(+) and CD8(+) T cells. Cyclin D1-specific T cells secrete IFN-γ. DCs loaded with whole tumor cells or with selected peptides can elicit cyclin D1-specific CD8(+) T cells that kill MCL tumor cells. We developed a recombinant vaccine based on targeting cyclin D1 antigen to human DCs via an anti-CD40 mAb. Targeting monocyte-derived human DCs in vitro with anti-CD40-cyclin D1 fusion protein expanded a broad repertoire of cyclin D1-specific CD4(+) and CD8(+) T cells.Conclusions
This study demonstrated that cyclin D1 represents a good target for immunotherapy and targeting cyclin D1 to DCs provides a new strategy for mantle cell lymphoma vaccine.
SUBMITTER: Chen J
PROVIDER: S-EPMC4424584 | biostudies-literature | 2015 Apr
REPOSITORIES: biostudies-literature
Chen Jingtao J Zurawski Gerard G Zurawski Sandy S Wang Zhiqing Z Akagawa Keiko K Oh Sangkon S Hideki Ueno U Fay Joseph J Banchereau Jacques J Song Wenru W Palucka A Karolina AK
Journal of hematology & oncology 20150414
<h4>Background</h4>Mantle cell lymphoma (MCL) is a distinct clinical pathologic subtype of B cell non-Hodgkin's lymphoma often associated with poor prognosis. New therapeutic approaches based on boosting anti-tumor immunity are needed. MCL is associated with overexpression of cyclin D1 thus rendering this molecule an interesting target for immunotherapy.<h4>Methods</h4>We show here a novel strategy for the development of recombinant vaccines carrying cyclin D1 cancer antigens that can be targete ...[more]